Is Digoxin Still Useful in Heart Disease?

Table of Contents
View All
Table of Contents

For over 200 years, digitalis (a substance derived from the foxglove plant), has been a mainstay in the treatment of heart disease—most specifically, heart failure and atrial fibrillation. Digoxin, by far the most commonly used form of digitalis, is still widely prescribed for the treatment of these cardiac conditions.

Foxglove plant
foxglove. itsabreeze photography / Getty images 

You might still be taking digoxin if you were prescribed this medication many years ago, or your doctor might prescribe it for you if newer treatment options are not considered beneficial for your condition.

In recent decades, digoxin has been prescribed less often than in the past because:

  • The benefits of several newer drugs have been proven in clinical trials, whereas there have been relatively few randomized trials demonstrating the benefits of digoxin.
  • Digitalis toxicity can be difficult to avoid and can be quite dangerous. There is less potential for toxicity with newer drugs.

Despite these concerns, digoxin can still be useful for the treatment of certain heart conditions.

How Digoxin Works

Digoxin has two major mechanisms of action that can help in the treatment of heart failure or atrial fibrillation:

  • Increasing the force of heart contractions: Digoxin inhibits certain pumps in the cardiac cell membranes, reducing the movement of sodium from the inside of cells to the outside of cells. By keeping sodium within the cells, it can help a weak heart muscle to pump a bit more effectively.
  • Slowing the heart rate: Digoxin affects autonomic tone, decreasing the conduction of electrical impulses through the AV node of a heartbeat. This can slow the heart rate in people with atrial fibrillation.

Digoxin Toxicity

Digoxin can become toxic above a certain threshold in the blood. Unfortunately, the therapeutic drug levels of digoxin are not that much different than the toxic blood levels. This narrow therapeutic window can make digoxin difficult to use safely for many people. Toxicity can even occur when the blood level is considered normal.

Digoxin toxicity is more likely if you have kidney problems or hypokalemia (low potassium levels), both of which are common in people who have heart failure or who take diuretics.

The toxic effects of digoxin can lead to:

Digoxin can also cause a loss of appetite, nausea or vomiting, and neurological problems such as confusion and visual disturbances.

Notably, around 30% of people with toxic digoxin levels will not experience any initial symptoms. This means that life-threatening cardiac arrhythmias caused by the drug can occur without warning.

If you are prescribed digoxin, your blood levels will be measured periodically to attempt to stay within the narrow therapeutic window.

Treatment of Heart Failure

As recently as 30 years ago, digoxin (along with diuretics) was the mainstay of treatment for heart failure due to dilated cardiomyopathy. This is a form of heart failure characterized by a reduced ejection fraction.

But since that time, several new treatments have demonstrated improved efficacy in numerous randomized clinical trials. These include beta-blockersACE inhibitors, ARB agents, and Entresto (sacubitril + valsartan).

In addition, sometimes heart failure is treated with cardiac resynchronization therapy, a treatment that can also significantly reduce symptoms and improve survival.

Some studies have shown that for people who have dilated cardiomyopathy, digoxin can improve the symptoms of heart failure and reduce the need for hospitalization. However, unlike newer therapies, it does not improve survival.

Most experts now recommend digoxin for the treatment of heart failure only if all other treatment options fail.

  • Digoxin offers no benefit if you have heart failure with a preserved ejection fraction (also known as diastolic heart failure).
  • Digoxin is also not useful for stabilizing acute heart failure.

Treatment of Atrial Fibrillation

Since a rapid heart rate is a chief cause of atrial fibrillation symptoms, digoxin can be useful in providing some relief of symptoms.

However, beta-blockers and calcium channel blockers, now commonly used to treat atrial fibrillation, are more effective for controlling symptoms of atrial fibrillation. These medications slow the heart rate both at rest and during exercise, whereas digoxin slows the heart rate only at rest. If you have atrial fibrillation and exercise intolerance, digoxin will not provide relief for your exercise intolerance.

Furthermore, there is evidence that digoxin is associated with an increase in mortality (risk of death) when used to treat atrial fibrillation.

A 2018 study in the Journal of American Cardiology suggests that the risk of mortality increases in tandem with the concentration of digoxin in the blood for people who have atrial fibrillation. One possible contributing cause is the risk of sudden death from cardiac arrhythmia.

Digoxin is used with extreme caution if you have atrial fibrillation. However, your doctor might consider prescribing it for you if you have persistent and significant symptoms at rest that are not relieved by a combination of beta-blockers and calcium channel blockers.

A Word From Verywell

Not long ago, digoxin was a mainstay of therapy for both heart failure and atrial fibrillation. However, in recent decades, newer drugs have proven to be more effective and safer to use.

With that said, digoxin still has its place in the treatment of these conditions. When used appropriately and under the supervision of a cardiologist, the drug may reduce symptoms and significantly improve your quality of life.

Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. David MNV, Shetty M. Digoxin. In: StatPearls [Internet]. Updated December 1, 2020.

  2. Currie GM, Wheat JM, Kiat H. Pharmacokinetic considerations for digoxin in older people. Open Cardiovasc Med J. 2011;5:130-5. doi:10.2174/1874192401105010130

  3. Cummings ED, Swoboda HD. Digoxin toxicity. In: StatPearls [Internet]. Updated July 10, 2021.

  4. MacLeod-Glover N, Mink M, Yarema, M. Digoxin toxicity: case for retiring its use in elderly patients? Can Fam Physician. 2016 Mar;62(3):223-8.

  5. Ambrosy AP, Butler J, Ahmed A, et al. The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. J Am Coll Cardiol. 2014 May 13;63(18):1823-32. doi:10.1016/j.jacc.2014.01.051

  6. Krim SR, Campbell PT, Desai S, et al. Management of patients admitted with acute decompensated heart failure. Ochsner J. 2015 Fall;15(3):284-9.

  7. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-200d. doi:10.1093/eurheartj/ehw128

  8. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update on the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation. 2019;140:e125-51. doi:0.1161/CIR.0000000000000665

  9. Virgadamo S, Charnigo R, Darrat Y, Morales G, Elayi CS. Digoxin: a systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. World J Cardiol. 2015 Nov 26;7(11):808-16. doi:10.4330/wjc.v7.i11.808

  10. Lopes RD, Rordorf R, De Ferrari GM, et al. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018 Mar 13;71(10):1063-74. doi:10.1016/j.jacc.2017.12.060